Shenzhen Salubris Pharmaceuticals Co., Ltd.
信立泰
002294
Shenzhen Stock Exchange
Company Profile
R&D is the sustainable driven force of the company. The over 600 R&D team located in Shenzhen, Chengdu and Maryland State, America.The investment for R&D was 0.439 billion yuan(RMB), occupying 10.57% of the revenue.Meanwhile, Salubris is in long-term collaboration with the R&D institutes and building research platforms together,achieving the transformation of domestic and international scientific and technological achievements. Salubris products combine generic and original products, establishing short-term, mid-term and long-term product portfolio strategy. The R&D projects include many innovative medicines. Chemical pharmaceuticals are included in short-term and mid-term strategy, which will be in the stage of rich the product line rapidly in the next 2 to 3 years. The innovative biological medicines are the middle- and long-term products planning, laying a foundation for the company to become an excellent biological enterprise. Salubris is patient-oriented and based on high quality products in the market. The products’ internal control standard is higher than that of the National Pharmacopoeia. As the first domestic enterprise achieved EU GMP certification on both API and Formulation of Clopidogrel, the product quality has been acknowledged worldwide. In the EBM (Evidence-base Medicine) promotion field, the professional promotion team has been highly acknowledged in areas of expertise. The distribution channels are across national Secondary and Tertiary Hospitals, which also extended to primary hospitals. In addition, Salubris has set up a marketing team in retail outlet, forming a vertical and full-covering sales network. In addition, Salubris established an academic platform with outstanding specialists and hospitals to conduct intensive evidence-based research. With the successful promotion of new products, Salubris’ profitability will be gradually improved.
Full description
Shenzhen Salubris Pharmaceuticals Co., Ltd (Salubris) was founded in 1998 and listed in the Small and Medium Enterprise Board of Shenzhen Stock Exchange in 2009. Salubris is a National High-tech Enterprise which specializes in the high-end chemical pharmaceuticals, biological medicines and biomedical fields. The company business focuses in the therapeutic fields of Cardiovascular, Anti-Diabetic, Antineoplastic and Orthopedic. In the cardiovascular field, the key products are all either innovative or the first launcher to the market. This has established a leading position in the industry. Excellent and systematic product chain layout and sales cover nationwide EBM (Evidence-base Medicine) Medical Reps are two of strengths of the company.Key products: TAIJIA, the first choice for antiplatelet aggregation, maintains competitive advantages and a steady growing. The 25mg and 75mg of TAIJIA are the first ones to pass the bio-equivalence assessment, which will accelerate the replacement of imported drugs. Secondly, XINLITAN, the sort 1.1 ARB Antihypertensive medicine, was included in NRDL. Currently, XINLITAN is in the stage of hospital admission and Phase IV clinical study, which is widely acknowledged by the experts in national top academic summits. TAIJIANING, the antithrombin drug, is in the stage of achieving sales volume rapidly and the potential increase, which has a absolute leading position in the market. Ticagrelor’s manufacturing filling was ongoing and was listed in the priority review list as “first generics” application from CDE. Our company also initiated core patent challenge against the originator and was successfully, from which it is believed the launch of this product will be accelerate. The launch of this product will form complementary advantages with TAIJIA and TAIJIANING. In the meantime, the company is also constantly reinforcing professional EBM (Evidence-base Medicine) Medical Reps Team building. Based on sufficient evidence-based evaluation, the team will provide high-quality products to the society by providing professional academic promotion and delivering product values. In the future, Salubris will be patient-centric and concentrate on “Meet the unmet medical needs”. The company will rapidly enrich the product pipeline and launch blockbuster products by many ways, such as independent innovation, technological cooperation and license-in. Salubris will gradually become a China-based international innovative pharmaceutical enterprise. In 2017, the company achieved its operating revenue of 4.15377 billion yuan (RMB), which increased 8.35% year on year. The pretax income was 1.71462 billion yuan which increased 5.18% year on year. The net profit attributable to shareholders was 1.45188 billion yuan (RMB), a year-on-year increase of 3.97%.